Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 11Recruiting 4Terminated 3Not yet recruiting 3Active not recruiting 3Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 6Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3Colonic Neoplasms 3Anus Neoplasms 3Sarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma in Situ 2Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Neoplasms by Site 1Neoplasm Recurrence, Local 1Nasopharyngeal Carcinoma 1Mycobacterium Infections 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Disease 1Dermatitis 1Carcinoma, Hepatocellular 1Adenoviridae Infections 1

Interventions

apaziquone 4Mitomycin 3viscum album peptide 1valrubicin 1pembrolizumab 1linrodostat 1enzalutamide 1enfortumab vedotin 1avelumab 1Sugars 1Standard of Care 1Polysorbates 1Pentosan Sulfuric Polyester 1Nivolumab 1Gemcitabine 1DDMS 1Capsules 1Bevacizumab 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Non-Muscle Invasive Bladder Neoplasms × Mitomycin × Clear all
NCT02106572 2026-05-22

TIM

Abnoba Gmbh

Phase 3 Terminated
174 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04688931 2024-06-06

ATLAS

UroGen Pharma Ltd.

Phase 3 Terminated
282 enrolled 29 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Samyang Biopharmaceuticals Corporation

Phase 3 Terminated
36 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡